FDA awards Novartis expanded approval for breast cancer therapy
Posted:
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But, the Food and Drug Administration approved Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers.
Currently more than 50 per cent of women are diagnosed with ovarian cancer at an advanced stage when fewer treatment options are available. A specialist medical tampon could be used to help diagnose ovarian cancer earlier, researchers believe.
Read more here.
A clinical trial into puberty blockers for children has been paused after the medicines regulator warned it should have a minimum age limit of 14 because of the “unquantified risk” of “long-term biological harms”.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us